Neuropeptides and Depression Beyond Serotonin

Neuropeptides and Depression

30% non-response

Roughly 30% of patients with major depression do not respond to serotonin-based antidepressants, driving research into neuropeptide alternatives.

Kupcova et al., Behavioral Sciences, 2022

Kupcova et al., Behavioral Sciences, 2022

The dominant model of depression for the past four decades has centered on monoamine neurotransmitters: serotonin, norepinephrine, and dopamine. This model produced SSRIs, SNRIs, and other medications that remain first-line treatments. But roughly 30% of patients with major depressive disorder do not respond adequately to these drugs, and the monoamine hypothesis fails to explain why antidepressants take weeks to work despite altering neurotransmitter levels within hours.^[1] Neuropeptides, a class of over 100 signaling molecules produced by neurons throughout the brain, offer a parallel biology of depression that operates through different mechanisms and different brain circuits.

This article maps the neuropeptides most implicated in depression research, from the stress-activating CRF system to the resilience-promoting NPY pathway to the social bonding effects of oxytocin. For deeper coverage of individual topics, see our dedicated articles on CRF and the stress hormone connection, substance P antagonists, the neuropeptide theory of depression, and VGF-derived peptide targets.

What Neuropeptides Are and How They Differ from Neurotransmitters

Neuropeptides are small protein molecules, typically 3 to 100 amino acids long, synthesized in neuronal cell bodies and transported to synaptic terminals. Unlike classical neurotransmitters (serotonin, dopamine, GABA, glutamate), which are synthesized locally at the synapse and act on millisecond timescales, neuropeptides are produced in the cell body, packaged into dense-core vesicles, and released under conditions of sustained or high-frequency neuronal firing. They diffuse over larger distances and act over seconds to minutes, modulating entire neural circuits rather than individual synapses.^[2]

This makes neuropeptides ideal regulators of sustained emotional states like mood, anxiety, and stress responses. A single burst of serotonin release may transiently alter synaptic signaling, but neuropeptide release can shift the baseline excitability of entire brain regions for extended periods. Many neuropeptides co-localize with classical neurotransmitters in the same neurons, creating layered signaling systems where the fast neurotransmitter handles moment-to-moment communication and the neuropeptide sets the longer-term tone.

Mechanism Comparison

Why neuropeptides could succeed where SSRIs fail

SSRIs (current standard)

Neuropeptide approach

What they target

Serotonin reuptake at synapses

Specific receptors in stress, resilience, and social circuits

Speed of action

Hours to change serotonin, weeks to affect mood

Can shift circuit activity within minutes to hours

Scope

Floods entire brain with serotonin

Circuit-specific — targets amygdala, hypothalamus, or hippocampus

Side effects

Sexual dysfunction, weight gain, emotional blunting

Varies by peptide — potentially fewer off-target effects

Non-response rate

~30% of patients don't respond

May reach the 30% that SSRIs miss

Current status

6+ approved drugs, decades of clinical use

Zero approved for depression — strong preclinical data

What they target

SSRI: Serotonin reuptake at synapses

Neuropeptide: Specific receptors in stress, resilience, and social circuits

Speed of action

SSRI: Hours to change serotonin, weeks to affect mood

Neuropeptide: Can shift circuit activity within minutes to hours

Scope

SSRI: Floods entire brain with serotonin

Neuropeptide: Circuit-specific — targets amygdala, hypothalamus, or hippocampus

Side effects

SSRI: Sexual dysfunction, weight gain, emotional blunting

Neuropeptide: Varies by peptide — potentially fewer off-target effects

Non-response rate

SSRI: ~30% of patients don't respond

Neuropeptide: May reach the 30% that SSRIs miss

Current status

SSRI: 6+ approved drugs, decades of clinical use

Neuropeptide: Zero approved for depression — strong preclinical data

Sources: Kupcova et al. (2022); Holmes et al. (2003); Kormos & Gaszner (2013)

View as image

The brain expresses over 100 distinct neuropeptides, but depression research has concentrated on a smaller group: corticotropin-releasing factor (CRF), neuropeptide Y (NPY), substance P, oxytocin, vasopressin, galanin, orexin/hypocretin, and more recently, VGF-derived peptides and ProSAAS-derived peptides.^[3]

CRF: The Stress Peptide Overactivated in Depression

Corticotropin-releasing factor (CRF, also called CRH) is a 41-amino acid neuropeptide that sits at the top of the hypothalamic-pituitary-adrenal (HPA) axis. CRF released from the hypothalamus triggers ACTH release from the pituitary, which drives cortisol production from the adrenal glands. But CRF also acts as a neurotransmitter in the amygdala, hippocampus, and cortex, where it modulates anxiety, fear, and mood independent of its hormonal effects.

CRF overactivity is one of the most replicated findings in depression neurobiology. Depressed patients show elevated CRF in cerebrospinal fluid, enlarged adrenal glands, and blunted ACTH responses to CRF challenge (indicating downregulated CRF receptors from chronic overstimulation). Reul and Holsboer (2002) documented that CRF acts through two receptor subtypes: CRF-1 receptors, which mediate anxiety-like behavior when activated, and CRF-2 receptors, which may have anxiolytic effects. This receptor duality complicates drug development but also creates opportunities for selective targeting.^[4]

Fan et al. (2014) demonstrated that prenatal stress programs the CRH peptide family system, altering CRF receptor expression in offspring and increasing vulnerability to anxiety and depression in adulthood. This finding connects early-life stress to adult neuropeptide dysfunction through epigenetic mechanisms.^[5]

Multiple pharmaceutical companies have developed CRF-1 receptor antagonists (pexacerfont, verucerfont, emicerfont), and while these showed antidepressant effects in animal models, clinical trials produced mixed results. The failure may reflect the complexity of CRF signaling rather than a flaw in the neuropeptide hypothesis itself. CRF acts differently in different brain regions: blocking CRF-1 in the amygdala may reduce anxiety, while blocking it in the prefrontal cortex may impair cognitive function needed for emotional regulation. Future approaches may need brain-region-specific delivery rather than systemic receptor antagonism.

Beyond the HPA axis, CRF peptides include urocortin I, II, and III, which preferentially activate CRF-2 receptors. Urocortin III produces anxiolytic effects in animal models, raising the question of whether CRF-2 agonism (not CRF-1 antagonism) might be the more productive therapeutic strategy. For the full clinical development history, see our article on CRF and the stress hormone connection.

Neuropeptide Y: The Resilience Peptide

Neuropeptide Y (NPY) is a 36-amino acid peptide and one of the most abundant neuropeptides in the mammalian brain. It is densely expressed in the amygdala, hippocampus, hypothalamus, and cortex. NPY consistently produces anxiolytic and antidepressant-like effects in animal models, and human studies associate higher NPY levels with stress resilience.

Cohen et al. (2012) used an animal model of PTSD to show that rats with higher NPY expression in the amygdala and hippocampus after traumatic stress showed fewer anxiety and depression-like behaviors. Crucially, this was not just a correlation: NPY expression patterns predicted which animals would be resilient versus vulnerable before behavioral testing. Exogenous NPY administration into the amygdala reduced anxiety behaviors, confirming a causal role.^[6]

Enman et al. (2015) reviewed the therapeutic potential of the NPY system in stress-related psychiatric disorders, documenting that NPY acts through five receptor subtypes (Y1-Y5), each with distinct effects. Y1 receptor activation in the amygdala produces anxiolytic effects. Y2 receptor blockade (Y2 receptors are presynaptic autoreceptors that limit NPY release) also reduces anxiety by increasing NPY availability. The multiplicity of NPY receptors creates multiple drug development opportunities.^[7]

Singanwad et al. (2025) extended NPY's role specifically to treatment-resistant depression (TRD), documenting that NPY modulates neuroplasticity through BDNF pathways, reduces neuroinflammation by suppressing microglial activation, and normalizes HPA axis dysregulation, three mechanisms that SSRIs address incompletely. The authors proposed NPY-based interventions as adjuncts for patients who fail conventional antidepressant therapy.^[8]

Human data supports this preclinical picture. Military studies found that Special Forces soldiers, who are selected and trained for extreme stress resilience, have higher plasma NPY levels than general military personnel. Combat veterans with PTSD show lower NPY levels than combat-exposed veterans without PTSD. This human correlational data aligns with the animal causal data showing NPY administration reduces stress vulnerability, creating one of the strongest translational cases in neuropeptide depression research.

Substance P and the NK1 Receptor

Substance P is an 11-amino acid neuropeptide of the tachykinin family that acts primarily through NK1 (neurokinin-1) receptors. It is expressed in brain regions involved in emotional processing, including the amygdala, hypothalamus, and periaqueductal gray. Depressed patients show elevated substance P levels in cerebrospinal fluid, and NK1 receptor density is increased in the brains of suicide victims.

The substance P story in depression includes one of the most dramatic rise-and-fall narratives in psychopharmacology. Merck's aprepitant (an NK1 antagonist originally developed for nausea) showed antidepressant effects in an early clinical trial in 1998, rivaling paroxetine's efficacy without sexual side effects. This triggered a rush of NK1 antagonist development across the pharmaceutical industry. Subsequent larger trials failed to replicate the effect, and most programs were abandoned.

Rotzinger et al. (2010) reviewed the preclinical evidence and noted that substance P antagonists consistently show antidepressant and anxiolytic effects in animal models, but the doses and brain concentrations required may not have been achieved in human trials. The disconnect between robust preclinical data and inconsistent clinical results remains one of the central puzzles in neuropeptide drug development.^[9] For the complete history, see our article on substance P antagonists for depression.

Neuropeptide Landscape

Eight peptide systems that shape depression — none of them serotonin

CRF

Corticotropin-Releasing Factor

Drives depression

Stress activation

Overactive in depression — drives cortisol, anxiety, HPA axis dysfunction

NPY

Neuropeptide Y

Protects against

Stress resilience

Higher levels = better stress coping. Special Forces soldiers have elevated NPY.

Substance P

Substance P / NK1

Drives depression

Emotional pain signaling

Elevated in cerebrospinal fluid of depressed patients and suicide victims

Oxytocin

Oxytocin

Protects against

Social bonding & trust

Reduces amygdala threat response. May counteract social withdrawal in depression.

Orexin

Orexin / Hypocretin

Complex role

Arousal & reward

Links sleep disruption, motivation loss, and reward processing in depression

Galanin

Galanin

Drives depression

Monoamine modulation

Suppresses serotonin and norepinephrine release when overactive after chronic stress

VGF

VGF-derived peptides

Protects against

Neuroplasticity

TLQP-62 promotes hippocampal neurogenesis — faster onset than SSRIs in animal models

ProSAAS

ProSAAS-derived peptides

Protects against

Novel anxiety target

GPR171 agonists reduced anxiety in mice. Among the most abundant brain peptides.

Sources: Holmes et al. (2003); Kormos & Gaszner (2013); Fricker et al. (2025)

View as image

Oxytocin: The Social Bonding Peptide

Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus and released both into the bloodstream (endocrine function) and within the brain (neuromodulatory function). It is central to social bonding, trust, and attachment. Depression is fundamentally a disorder of social withdrawal, anhedonia, and disconnection, making oxytocin a logical candidate for investigation.

Kirsch et al. (2005) demonstrated that intranasal oxytocin administration in healthy humans reduced amygdala activation in response to fearful faces, showing that oxytocin can directly modulate the threat-processing circuitry that is overactive in depression and anxiety disorders. The amygdala dampening occurred without affecting amygdala responses to happy or neutral faces, suggesting a selective reduction in threat sensitivity rather than a blunting of all emotional processing.^[10]

The oxytocin system interacts bidirectionally with the serotonin system. Oxytocin neurons in the hypothalamus express serotonin receptors (particularly 5-HT1A), and serotonin release in the hypothalamus stimulates oxytocin secretion. This creates a pathway through which SSRI antidepressants may exert some of their therapeutic effects indirectly through oxytocin, partially explaining why SSRIs improve social anxiety and interpersonal functioning beyond what pure serotonin elevation would predict.

However, oxytocin's effects are context-dependent and dose-dependent. In some social situations, oxytocin increases in-group trust but also out-group suspicion. At low doses it may reduce anxiety, while at higher doses it can increase salience of social threats. Individuals with insecure attachment styles may respond differently to oxytocin than those with secure attachment. This complexity has slowed its development as a standalone antidepressant, though it remains a promising adjunct for social anxiety and depression subtypes characterized by interpersonal withdrawal.

Vasopressin, oxytocin's structurally similar nine-amino-acid cousin (differing by just two amino acids), has complementary effects in social behavior. Where oxytocin generally promotes affiliation, vasopressin is more associated with vigilance and mate-guarding behaviors. The oxytocin-vasopressin balance may be relevant to depression subtypes characterized by anxiety-predominant versus withdrawal-predominant presentations.

Orexin/Hypocretin: Linking Arousal, Reward, and Mood

The orexin peptides (orexin-A and orexin-B, also called hypocretin-1 and hypocretin-2) are produced by a small cluster of neurons in the lateral hypothalamus. They are best known for regulating wakefulness (loss of orexin neurons causes narcolepsy), but they also modulate reward processing, stress responses, and mood through projections to the VTA, locus coeruleus, and amygdala.

Cohen et al. (2020) showed that the orexinergic system modulates stress-related behaviors through interactions with the serotonergic and noradrenergic systems. In a PTSD animal model, orexin-1 receptor antagonism reduced anxiety-like behaviors, while orexin-2 receptor modulation affected sleep architecture and arousal. The dual-receptor system creates the same kind of complexity seen with CRF: one receptor subtype may promote stress responses while the other may counteract them.^[11]

Suvorexant (Belsomra) and lemborexant (Dayvigo), approved dual orexin receptor antagonists for insomnia, provide an opportunity to study orexin blockade effects on mood in clinical populations. Early observations suggest that orexin antagonism may improve sleep-related depression symptoms, though dedicated depression trials are lacking. For more on orexin biology, see our article on narcolepsy and orexin neurons.

Galanin: The Underexplored Modulator

Galanin is a 29-amino acid neuropeptide (30 in humans) with widespread expression in the brain, particularly in the locus coeruleus, dorsal raphe, and hypothalamus, regions central to noradrenergic and serotonergic function. Galanin co-localizes with both norepinephrine and serotonin in these nuclei, positioning it as a direct modulator of the monoamine systems targeted by conventional antidepressants.

Kask et al. (1997) described galanin's involvement in depression through its inhibitory effects on norepinephrine and serotonin release. Galanin acts through three receptor subtypes: GalR1 (inhibitory, linked to depression-like behavior), GalR2 (potentially antidepressant), and GalR3 (anxiogenic in some models). The pattern mirrors other neuropeptide systems: receptor subtype determines whether the peptide's effects are pro-depressive or antidepressive.^[12]

Galanin levels rise in the locus coeruleus after chronic stress, potentially contributing to noradrenergic blunting and the emotional numbness characteristic of depression. This is particularly relevant because the locus coeruleus is the primary source of norepinephrine in the brain, and its dysfunction is central to the fatigue, concentration difficulties, and psychomotor retardation seen in depression. Galanin-mediated suppression of locus coeruleus firing may explain why some depressed patients respond poorly to norepinephrine-targeting drugs like SNRIs: the problem is not norepinephrine receptor sensitivity but upstream peptide-mediated suppression of norepinephrine release.

GalR2 agonists show antidepressant effects in animal models, and GalR3 antagonists reduce anxiety-like behavior, but no galanin-targeting drugs have reached clinical trials for depression. The galanin system exemplifies the receptor-subtype challenge: three receptors with different, sometimes opposing functions in the same brain circuits. For more on galanin, see our article on galanin as a sleep-promoting peptide.

Emerging Targets: ProSAAS and VGF-Derived Peptides

Two newer classes of neuropeptides are entering the depression research landscape. ProSAAS-derived peptides are among the most abundant peptides in the brain, with levels comparable to enkephalin and NPY, yet they remained functionally uncharacterized until recently. Fricker et al. (2025) identified two receptors for ProSAAS peptides, GPR171 and GPR83, and demonstrated that modulating these receptors affects anxiety-related behavior and body weight in animal models. GPR171 agonists reduced anxiety-like behavior in mice, positioning ProSAAS peptides as a genuinely novel target class.^[13]

VGF (non-acronymic) is a neuropeptide precursor that produces multiple bioactive fragments, including TLQP-62 and TLQP-21. VGF expression is induced by BDNF and by antidepressant treatment, and VGF-derived peptides produce antidepressant-like effects in rodent models. TLQP-62 infusion into the hippocampus promotes neurogenesis and produces behavioral effects comparable to chronic SSRI treatment but with faster onset. The VGF pathway is notable because it sits downstream of the BDNF-TrkB signaling cascade that is increasingly recognized as central to antidepressant mechanism of action. This positions VGF peptides as potential mediators of the antidepressant effects that current drugs produce indirectly and slowly through monoamine modulation.

Both ProSAAS and VGF-derived peptides illustrate a recurring pattern: neuropeptides discovered through basic neuroscience (not psychiatry) turn out to have mood-regulatory functions that were invisible under the monoamine framework. The brain's peptide signaling system is far more complex than the three-neurotransmitter model that dominates clinical teaching. For a complete analysis of VGF, see our article on VGF-derived peptide targets.

Why Neuropeptide Drugs Have Been Difficult to Develop

Despite decades of compelling preclinical data, no neuropeptide-targeting drug has been approved specifically for depression. Several factors explain this gap. Neuropeptides do not cross the blood-brain barrier easily, requiring either intranasal delivery, intrathecal injection, or development of small-molecule receptor agonists/antagonists that mimic the peptide's effects. The receptor subtype complexity described above means that drugs must be highly selective, as activating one receptor subtype may produce therapeutic effects while activating another produces the opposite.

Satao and Doshi (2024) reviewed the current state of neuropeptide-based anxiety treatments and identified additional challenges: peptide degradation by brain enzymes, difficulty achieving consistent brain concentrations, and the absence of validated biomarkers to select patients most likely to benefit. These are solvable engineering problems, not fundamental biological obstacles. Advances in peptide stabilization (cyclization, D-amino acid substitution, PEGylation) and delivery (intranasal formulations, nanoparticle encapsulation, lipid-based carriers) are gradually closing the gap between preclinical promise and clinical viability.^[14]

Drug Development Pipeline

Strong science, zero approved drugs — where each neuropeptide target stands

CRF-1 antagonists

Clinical failure

Pexacerfont, verucerfont — antidepressant effects in animals, mixed clinical results

Barrier: Brain-region-specific effects hard to achieve with systemic drugs

NK1 antagonists (Substance P)

Clinical failure

Aprepitant showed promise in 1998, but larger trials couldn't replicate

Barrier: May need higher brain concentrations than oral dosing achieves

NPY agonists

Preclinical

Strongest resilience data; Special Forces link. No drugs in human trials.

Barrier: NPY doesn't cross blood-brain barrier; delivery is the bottleneck

Intranasal oxytocin

Early clinical

Reduces amygdala threat response. Adjunct trials ongoing.

Barrier: Context-dependent effects; dose-response is complex

Orexin antagonists

Approved (other)

Suvorexant/lemborexant approved for insomnia; depression effects being studied

Barrier: Approved for sleep, not depression — repurposing data needed

GalR2 agonists

Preclinical

Antidepressant effects in animals; no compounds in human trials

Barrier: Three receptor subtypes with opposing effects

VGF-derived peptides

Preclinical

TLQP-62 promotes neurogenesis faster than SSRIs in animals

Barrier: Very early; delivery and formulation not yet addressed

ProSAAS / GPR171

Preclinical

Newly characterized receptors; anxiolytic effects in mice

Barrier: Discovery-stage — receptors identified in 2025

Sources: Satao & Doshi (2024); Rotzinger et al. (2010); Fricker et al. (2025)

View as image

The neuropeptide theory of depression does not replace the monoamine hypothesis. Instead, it expands it. Neuropeptides modulate the same brain circuits (amygdala, prefrontal cortex, hippocampus, hypothalamus) and interact directly with the same monoamine systems that current drugs target. The difference is resolution: neuropeptides offer finer-grained control over specific emotional and stress-response circuits, potentially enabling treatments tailored to specific depression subtypes rather than the one-size-fits-all approach of SSRIs. For the theoretical framework, see our article on the neuropeptide theory of depression.

Other neuropeptides relevant to depression biology include dynorphin and the kappa opioid receptor, which drives dysphoria, and beta-endorphin, which mediates natural reward and pleasure, both directly relevant to the anhedonia that defines depressive experience. The endogenous opioid peptide system represents yet another layer of neuropeptide regulation that intersects with depression biology at the level of reward, pain, and social connection.

The Bottom Line

Neuropeptides including CRF, NPY, substance P, oxytocin, orexin, galanin, and newer targets like ProSAAS and VGF-derived peptides operate through distinct mechanisms from serotonin-based antidepressants and regulate the stress, resilience, social bonding, and arousal circuits disrupted in depression. The 30% non-response rate to SSRIs and the weeks-long delay in their therapeutic effects suggest that monoamine modulation alone is insufficient for many patients. Neuropeptide-based treatments face pharmacological delivery challenges, but the biology is well-established, and multiple receptor targets remain available for drug development.